Altmann Analytik acquires Technolab GmbH
Altmann Analytik GmbH & Co KG has acquired Technolab GmbH. With this decision, the independent specialist distributor Altmann Analytik expands its product and customer portfolio and strengthens its presence in North Rhine-Westphalia.
Founded in 1988, the company primarily serves customers in the food industry and is firmly anchored in western and northern Germany. One of Technolab's particular strengths is the fast and reliable delivery of nutrient media and agars, most of which are kept in stock at the modern warehouse in Schwerte. Altmann Analytik takes over the location as well as all employees of Technolab GmbH. Together with Tobias Thelen of Altmann Analytik, Raphael DeVol will take over the management of the company. The current managing director of Technolab GmbH, Philipp Enste, will continue to support the company until the end of the year.
Tobias Thelen, Managing Director of Altmann Analytik, commented on the takeover: "We are delighted to be gaining motivated colleagues in the experienced Technolab team, with whom we will be able to offer our customers an even broader product portfolio and shorter delivery times. Technolab will benefit from Altmann Analytik's online expertise. Together, we can offer our customers expert advice across the entire laboratory range and now supply them from two strategically located sites in Germany," explains Managing Director Tobias Thelen.
Philipp Enste, outgoing Managing Director of Technolab GmbH: "I have known Altmann Analytik for many years and am delighted to be able to hand over Technolab into capable hands. Nothing will change for our customers - they can expect the same excellent service as before. I am convinced that the two companies will complement each other perfectly and together create added value for customers," says Philipp Enste.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Protagen Deepens Cooperation With Bayer Schering Pharma
Seeing a diagnosis: How an eye test could aid Alzheimer's detection
C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring
New technique for testing drugs to treat cystic fibrosis and epilepsy
Neuronal Parkinson inclusions are different than expected - Study raises new questions about the etiology of Parkinson’s disease
Analytik Jena Sells Site in Eisfeld - New investor acquiring entire Optics business unit as well as component production for analytical technology
Toxic agents behind Parkinson's disease seen at work for the first time - First look at how toxic protein clusters disrupt the membranes of healthy brain cells.
Ocean Optics Employee Wins Global Technology Award - Nelson Chandler takes £20K top prize from multi-national technology company
Measuring the magnetism of antimatter - Researchers measure antiprotons more accurately than ever before
KRÜSS is one of the innovation leaders in 2018 - TOP 100 competition success
COVID-19 : Measuring viral RNA to predict which patients will die - A statistical model uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19